Lilly’s Verzenio plus fulvestrant improves overall survival in MONARCH 2
The late-stage study called MONARCH 2 met its secondary endpoint of overall survival for Verzenio in combination with the endocrine therapy fulvestrant. The trial involved 669 patients, who